Breaking News: First Patient Receives Dose in Phase 2 Trial of JSKN003 for Advanced HER2-Low Breast Cancer Treatment
Alphamab Oncology Doses First Patient in Phase III Clinical Study for HER2-Low Breast Cancer Treatment SUZHOU, China, Dec. 4, 2023 /PRNewswire/ — Alphamab Oncology (stock code: 9966.HK) announced the first patient has been dosed in the phase III clinical study (JSKN003-302) of anti-HER2 bispecific antibody-drug conjugate JSKN003 for treatment of advanced HER2-low breast cancer. Breast…